Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813300 | PMC |
| http://dx.doi.org/10.4103/jrms.JRMS_854_17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamics and triggers of misinformation on vaccines.
PLoS One
January 2025
Centro Ricerche Enrico Fermi, Rome, Italy.
The Covid-19 pandemic has sparked renewed attention to the risks of online misinformation, emphasizing its impact on individuals' quality of life through the spread of health-related myths and misconceptions. In this study, we analyze 6 years (2016-2021) of Italian vaccine debate across diverse social media platforms (Facebook, Instagram, Twitter, YouTube), encompassing all major news sources-both questionable and reliable. We first use the symbolic transfer entropy analysis of news production time-series to dynamically determine which category of sources, questionable or reliable, causally drives the agenda on vaccines.
View Article and Find Full Text PDFThe Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.
Protein Cell
January 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Despite their therapeutic potential, the use of ADCs faces significant challenges, including off/on-target toxicity and resistance development. This review examines the current landscape of ADC development, focusing on the critical aspects of target selection and antibody engineering.
View Article and Find Full Text PDFA non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent mutant colorectal cancer.
Heliyon
January 2025
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with -mutant colorectal cancer.
Methods: In the interval between completing CRT and pelvic exenteration, patients with resectable mutation-positive, locally advanced primary or current colorectal cancer, received 5-6 doses of TG02/GM-CSF.
[Pharmacovigilance of COVID-19 Vaccines in Brazil: Actions Taken, Lessons Learned, and Next StepsFarmacovigilancia de las vacunas contra la COVID-19 en Brasil: medidas adoptadas, enseñanzas extraídas y próximos pasos].
Rev Panam Salud Publica
January 2025
Ministério da Saúde Brasília-DF Brasil Ministério da Saúde, Brasília-DF, Brasil.
Objective: To document the actions taken by Brazil's National Immunization Program for the pharmacovigilance of COVID-19 vaccines.
Methods: Documentary research on the period 2020 to 2023. Documentary sources from the national Ministry of Health during COVID-19 vaccination were used to analyze and interpret the actions taken.
Prevalence and factors contributing to missed opportunities for vaccination in Mogadishu, Somalia.
IJID Reg
March 2025
African Field Epidemiology Network, Kampala, Uganda.
Objectives: Vaccination is a critical public health intervention that significantly reduces morbidity and mortality from vaccine-preventable diseases. Despite the proven benefits of vaccines, missed opportunities for vaccination (MOVs) remain a significant challenge in many low-income countries, including Somalia. This study aimed to determine the prevalence and identify the factors contributing to MOVs in Mogadishu, Somalia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!